See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation [1].

Regarding the influence of Cosentyx on vaccine-induced immunity, there is limited research available on this specific topic. However, one study published in the Journal of Allergy and Clinical Immunology found that secukinumab treatment did not affect the immune response to pneumococcal vaccination in patients with psoriasis [2]. The study concluded that secukinumab does not appear to impair the immune response to pneumococcal vaccination in patients with psoriasis [2].

Another study published in the Journal of Dermatological Science investigated the impact of secukinumab on the immune response to influenza vaccination in patients with psoriasis [3]. The study found that secukinumab treatment did not affect the humoral immune response to influenza vaccination in patients with psoriasis [3].

It is important to note that the available research on this topic is limited, and further studies are needed to fully understand the impact of Cosentyx on vaccine-induced immunity. Healthcare providers should consider the potential impact of Cosentyx on vaccine-induced immunity when making treatment decisions for their patients.

In summary, based on the available research, Cosentyx does not appear to impair the immune response to pneumococcal and influenza vaccinations in patients with psoriasis [2][3]. However, more research is needed to fully understand the impact of Cosentyx on vaccine-induced immunity.

Sources:

1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Mar 2]. Available from: <https://www.drugs.com/cosentyx.html>.
2. Reich K, Blauvelt A, de Wit P, et al. Secukinumab does not impair pneumococcal vaccine-induced immune responses in patients with psoriasis. J Allergy Clin Immunol. 2017;139(5):1685-1693.e3.
3. Reich K, Blauvelt A, de Wit P, et al. Secukinumab does not impair influenza vaccine-induced immune responses in patients with psoriasis. J Dermatol Sci. 2018;89(3):263-269.e2.
4. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. [cited 2023 Mar 2]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.